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The cost of whole-genome sequencing (WGS) is decreasing rapidly as next-generation sequencing technology continues to ad-
vance, and the prospect of makingWGS available for public health applications is becoming a reality. So far, a number of studies
have demonstrated the use ofWGS as an epidemiological tool for typing and controlling outbreaks of microbial pathogens. Suc-
cess of these applications is hugely dependent on efficient generation of clean genetic material that is free from host DNA con-
tamination for rapid preparation of sequencing libraries. The presence of large amounts of host DNA severely affects the effi-
ciency of characterizing pathogens usingWGS and is therefore a serious impediment to clinical and epidemiological sequencing
for health care and public health applications. We have developed a simple enzymatic treatment method that takes advantage of
the methylation of human DNA to selectively deplete host contamination from clinical samples prior to sequencing. Using ma-
laria clinical samples with over 80% human host DNA contamination, we show that the enzymatic treatment enriches Plasmo-
dium falciparumDNA up to9-fold and generates high-quality, nonbiased sequence reads covering>98% of 86,158 catalogued
typeable single-nucleotide polymorphism loci.
Whole-genome sequencing (WGS) is beginning to providenew and efficient opportunities for the diagnosis and con-
trol of many clinically relevant pathogenic infections (1–5). High-
resolution WGS is promising to be the most informative typing
method (6) and is likely to be more sensitive than the traditional
culture-based diagnostic procedures in clinical microbiology (1,
2, 4, 7). As the technology is moving from bench to bedside (8–
10), sample quality and quantity have become a major technical
bottleneck in clinical sequencing. A large proportion of field-de-
rived pathogen specimens are heavily contaminatedwith hostma-
terial. Attempts to sequence these samples without adequate re-
moval of the host DNA negate some of the cost benefit realized by
the current advances in sequencing technology (11). Whereas
problems associated with the small amounts of starting material
have been addressed extensively through the development of al-
ternative library preparation methods as well as the discovery of
novel amplification technologies (12–14), host contamination has
remained a big challenge, especially for pathogens that are very
difficult to culture in vitro.
Due to the small size of pathogen genomes in comparison to
that of the genome of their host, the presence of just a few nucle-
ated human cells in a pathogen clinical specimen can completely
inundate that sample with host DNA contamination (11). Direct
sequencing of host-contaminated samples is inefficient and there-
fore not cost-effective. For example, one lane of an IlluminaHiSeq
system run has the capacity to sequencemore than 50multiplexed
pathogen genomes that are pure; however, this capacity is reduced
to only a single or a very few samples—with maintenance of ade-
quate coverage depth—when contaminated pathogen DNA is
used. Similarly, smaller benchtop systems—like the Ion Torrent
PGM (Life Technologies), MiSeq (Illumina), and 454 GS Junior
(Roche) systems—are likely to produce very little pathogen se-
quence from contaminated samples, reporting data mainly from
the overly abundant host material. It is therefore beneficial and
cost-effective to remove host DNA contamination prior to se-
quencing of pathogen clinical samples.
Here, we report an enzyme-based DNA degradation method
that selectively digests and depletes human DNA contamination
from malaria clinical samples, thereby enriching the parasite ma-
terial for high-throughput next-generation sequencing (NGS).
This approach takes advantage of the differential methylation pat-
terns that exist between host DNA and most pathogen genomes.
We have identified the recently characterized modification-de-
pendent restriction endonucleases (MD-REs) and harnessed their
unique activities to selectively degrade human host DNA in clin-
ical samples. MspJI (from Mycobacterium spp.), LpnPI (from
Legionella pneumophila), and FspEI (from Frankia spp.) are ho-
mologous enzymes belonging to the Mrr superfamily of endonu-
cleases that bind and cut nearmethylatedDNAbase pairs (15–17).
Although these enzymes display different sequence recognition
preferences, they all cleave at position N-12/N-16 on the 3= side of
methylated cytosines (15). DNAmethylation in higher eukaryotes
is dynamic and is affected by cellular processes that include differ-
entiation, genome regulation, and disease conditions (18). In hu-
mans, methylated cytosine is known to occur predominantly in
the context ofmethyl-CpGs and at an estimated frequency of 60%
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to 90% in that context (19, 20). Complete digestion of a contam-
inated clinical sample with methylation-dependent endonu-
cleases is therefore expected to result in significant degradation of
the host DNA and, consequently, enrich pathogen DNA. To test
this hypothesis, we first assessed the effect of the enzymes on pure
Plasmodium falciparum DNA and in mock host-contaminated
samples. We then assessed the ability of the enzymes to deplete
human host DNA in authentic highly contaminatedmalaria-con-
taining clinical samples. Here we report our findings and recom-
mendations on the use of MD-REs in degrading human DNA
frommalaria clinical samples to enrich for parasite DNA prior to
NGS.
MATERIALS AND METHODS
DNA samples. P. falciparum 3D7 genomic DNAwas obtained fromChris
Newbold’s laboratory at the University of Oxford, Oxford, United King-
dom. Other P. falciparum genomic DNA samples were samples of clinical
isolates containing80 to 90% humanDNA contamination. The clinical
isolates were obtained from the Malaria Genetics Group’s Sequencing
Sample Repository at the Wellcome Trust Sanger Institute. All clinical
samples were positive for P. falciparum by microscopic analysis. Human
genomic DNA was purchased from Promega (Madison, WI). Mock sam-
ples were manually reconstituted by mixing 100 ng of pure P. falciparum
3D7 genomic DNAwith 900 ng of pure human genomic DNA to obtain 1
g of a simulated clinical genomic DNA sample.
Methylation-dependent digestion. Digestion with methylation-de-
pendent restriction endonucleases was performed in 0.2-ml PCR tubes.
The reaction mixture (total volume, 30 l), containing 1NEB buffer 4,
10 g of bovine serum albumin, and 6 units of MD-RE (New England
BioLabs, MA), was placed in a thermocycler programmed to incubate at
37°C for 16 h, followed by heating at 65°C for 20 min to inactivate the
enzymes, prior to cooling to 4°C. It has been shown that the cleavage
activity of MD-REs is enhanced by inclusion of an activator sequence in
the digestion reaction (17). The activator is a short double-stranded oli-
gonucleotide designed to form a stem-loop structure and contains two
methylation (m) sites (CTGCmCAGGATCTTTTTTGATCmCTGGC
AG). The activator oligonucleotide was purchased from Integrated DNA
Technologies (Coralville, IA). For reactions involving the activator, 0.05
M oligonucleotide was used.
Gel-based sample preparation. For procedures involving gel separa-
tion, genomic DNA (1 to 2 g) was digested with MspJI as described
above under “Methylation-dependent digestion.” After digestion, the en-
tire reaction mixture was loaded on a 1% agarose-TBE (Tris-borate-
EDTA) gel containing SYBR green and resolved at 60 V for 45 min. High-
molecular-weight bands containing undigested genomic DNA (Fig. 1i
and ii) were excised and weighed before extracting the DNA using a
QIAEX II gel extraction kit (Qiagen, Germany) following the manufac-
FIG 1 Differential human DNA degradation analysis and separation procedures. (i) Agarose gel electrophoresis analysis of pure human and P. falciparum
genomic DNA incubated in the absence () or presence () of MspJI enzyme. (ii) A mixture comprising 90% human and 10% P. falciparum genomic DNA
incubated in the absence () or presence () of MspJI enzyme. (iii) Agilent bioanalyzer fragment analysis of mixtures of human and P. falciparum DNA. (A)
Fragment sizes of a Covaris-treated randomly shearedmixture of human and P. falciparum genomic DNA beforeMspJI digestion; (B) fragment size distribution
of the sheared DNA after MspJI digestion; (C) fragment size distribution of the MspJI-digested DNA after Ampure XP size selection that removes degraded
humanDNA and enriches for the larger undigested parasite DNA fragments; (D) fragment size distribution of a PCR enriched adapter-ligatedDNA library prior
to sequencing. FU, fragment units (i.e., number of fragments).
Oyola et al.
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turer’s instructions. Briefly, weighed gel slices were put in 2-ml Eppendorf
tubes and bufferQX1was added (3 volumes of buffer to 1 g of gel). The gel
was allowed to dissolve by incubating at room temperature with agitation
for 20 min or until complete dissolution. To bind the DNA, 10 l of
QIAEX II silica gel particles was added, and incubation was continued for
a further 10 min with agitation. Samples were centrifuged for 30 s at
10,000  g, and the supernatant was carefully removed. The pellet was
washed once with 500 l of buffer QX 1 and twice with 500 l of wash
buffer (PE). The pellet was air dried for 15 min, and the DNA was eluted
in elution buffer (EB). ElutedDNAwas sheared to350 bpwith aCovaris
S2 sonicator (Covaris Inc., Woburn, MA) using the settings described
below under “Illumina sequencing library preparation.” Sheared frag-
ments were processed to generate Illumina sequencing libraries.
Gel-free sample preparation. Genomic DNA (0.1 to 2 g) was
sheared to obtain random fragments with an average size of 350 bp
using a Covaris S2 sonicator. Fragments (Fig. 1iiiA) were end repaired as
described below under “Illumina sequencing library preparation.” End-
repaired samples were digested with MspJI as described above under
“Methylation-dependent digestion.” Digested samples (Fig. 1iiiB) were
size selected using Agencourt Ampure XP beads (Beckman Coulter Inc.,
Beverly, MA) following the manufacturer’s instructions with slight mod-
ifications. Briefly, equal volumes of beads and the digested sample were
mixed and incubated for 5 min at room temperature. After incubation,
the tube containing the bead-DNAmixture was placed on amagnetic rack
to capture the DNA-bound beads and the unbound solution was dis-
carded. Beads were washed twice with 80% ethanol, and the bound DNA
was elutedwith EB. Two rounds of this purification step ensure removal of
smaller fragments generated by MspJI digestion. Purified samples
(Fig. 1iiiC) were processed to generate Illumina paired-end libraries
throughA tailing, PE-adapter ligation and enrichment by 12 cycles of PCR
(Fig. 1iiiD), as described below under “Illumina sequencing library prep-
aration.”
Illumina sequencing library preparation. Genomic DNA (0.05 to 2
g) in 75l TE (Tris-EDTA) bufferwas sheared for 70 s using aCovaris S2
device. To obtain an average fragment size of350 bp, the settings used
were 10% duty cycle, intensity 4, and 200 cycles per burst. Illumina
paired-end sequencing libraries were constructed using an NEBNext
DNA sample preparation kit (New England BioLabs) following the stan-
dard Illumina sample preparation protocol (13). All PCR library amplifi-
cations, after adapter ligation, were performed with anMJ Research PTC-
225 thermocycler. Illumina PE 1.0 and 2.0 primers or PE 1.0- and
2.0-derived indexing primers were used to amplify 10 ng adapter-ligated
library fragments by PCR. Libraries were amplified using optimized PCR
conditions (13). Briefly, the PCR mixture with KAPA HiFi (KAPA Bio-
systems, SouthAfrica) contained 1KAPAHiFimastermix, 0.4Meach
primer pair, and 10 ng ofDNA in a 50-l volume. Amplification reactions
were performed using the following thermocycling conditions: 1 min at
98°C for the initial denaturation, followed by 12 cycles of 10 s at 98°C and
1 min at 65°C and a final extension for 5 min at 65°C.
Sequencing. DNA libraries were sequenced at the Wellcome Trust
Sanger Institute using IlluminaMiSeq andHiSeq 2000 instruments. Sam-
ples were sequenced using Illumina (version 3) chemistry; paired-end
sequencing was done with 75-base reads and an 8-base index read.
Data analysis. Sequence data obtained from each sample were sub-
jected to standard Illumina quality control procedures before detailed
analysis for enrichment and quality of coverage. For enrichment analysis,
we counted the number of reads mapping to either human or P. falcipa-
rum reference genome sequences. Each data set was analyzed indepen-
dently by mapping sequence reads to the reference genome using Bur-
rows-Wheeler Aligner (BWA) (21). SAMtools (21) was used to generate
coverage statistics from the BWA mapping output.
Nucleotide sequence accession number. All data sets used in this
study have been deposited in the European Nucleotide Archive read ar-
chive under accession number ERP000832.
RESULTS
Differential genomic endonuclease activity assay. Genomic
DNA methylation has been extensively studied in bacteria and
higher eukaryotic organisms, but little is known about the extent
and form of such modifications in eukaryotic pathogens. To de-
termine whether MD-REs have endonuclease activity on the
genomic DNA of an important eukaryotic pathogen, we per-
formed an in vitro digestion assay on DNA extracted from the
malaria parasite P. falciparum. As a positive control, a parallel
assaywas performed onhumanDNA.To control against any non-
enzymatic degradation, P. falciparum genomic DNA was incu-
bated in the presence of all the reagents present in the digestion
reaction except the enzyme. As shown in Fig. 1i, positive endonu-
clease activity, which results in shorter fragments (seen as a smear
below the main band), was observed only in the human genomic
DNA sample that was incubated in the presence ofMspJI enzyme.
P. falciparum DNA samples incubated in the presence or absence
of the enzyme remained intactwithout visible degradation. Amix-
ture of human and parasite DNA (90%humanDNAbymass) was
also digested and analyzed by gel electrophoresis. As shown in Fig.
1ii, degradation of the human DNA was also observed. Presum-
ably, the remainingDNAband contained themalaria component.
This indicates a selective endonuclease activity exhibited by the
MD-RE on human DNA. To further confirm that MD-RE diges-
tion had no degradation activity on P. falciparum DNA, we pre-
pared MspJI-treated and nontreated DNA for sequencing using
Illumina technologies. Nondegraded parasite DNA was separated
from degraded host DNA using either agarose gel electrophoresis
(Fig. 1i and ii) or magnetic bead-based size selection (Fig. 1iii).
Effect of activator sequence onMD-RE activity. Cleavage ac-
tivity of MD-REs has been shown to be enhanced by inclusion of
an activator sequence in the digestion reaction (17). We per-
formed an assay to detect the effect of this activator using the host
DNA depletion reaction. Data analysis indicates no significant
improvement to the overall enrichment of parasite DNA under
the reaction conditions tested (Fig. 2A). However, a detailed anal-
ysis of the enriched sequence data (Fig. 3A and B) indicates a
possible nonspecific degradation induced by the presence of the
activator. We compared the quality of sequence data generated
from samples treated in the absence (Fig. 3, sample 90HsPf-
TGNA) or presence (Fig. 3, sample 90HsPf-TGA) of the activator
sequence and observed a slightly biased base composition (higher
GCcontent; Fig. 3A; Table 1) anduneven genome coverage (Fig.
3B) in samples where digestion was supplemented with activator.
Due to these observations, the activator was excluded in all subse-
quent assays.
Gel and bead size selection. To separate degraded host frag-
ments from the nondegraded pathogen DNA, we used either gel
electrophoresis ormagnetic bead-based size-selection procedures.
The magnetic bead-based size selection allows high-throughput
automation of the entire sample preparation through to the final
library creation. As shown in Fig. 1iiiA, randomly sheared frag-
ments are subjected to MD-RE digestion after end repair, during
which host DNA fragments that are methylated are degraded to
smaller fragments of about 150 bp (Fig. 1iiiB). The digestion prod-
uct is subjected to magnetic bead-based size selection, where par-
asite DNA fragments are enriched relative to the degraded host
DNA (Fig. 1iiiC). Purified adapter-ligated product is then ampli-
fied by PCR to generate a final library, which is shown in Fig. 1iiiD.
Depletion of Host Contamination in Clinical Sequencing
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Comparative analysis of samples processed through either gel- or
bead-based procedures indicates slightly higher enrichment effi-
ciency in gel-separated samples (Fig. 2B); however, the quality of
data (in terms of uniformity of coverage) generated via both pro-
cedures was largely similar (Fig. 3).
Enrichment of pathogenDNA in human host-contaminated
samples. MspJI treatment selectively degrades human host DNA
with no detectable effect on pathogenDNA. Thismakes it suitable
for applications requiring removal of host contamination during
microbial clinical sequencing. To test this application, we pre-
pared mock samples (1 g total DNA) consisting of 10% parasite
and 90% human DNA by mass. We treated these samples with
MspJI and purified nondegraded DNA using either gel- or mag-
netic bead-based size-selection procedures (Fig. 2). Posttreatment
analysis indicates a recovery of70 ng of undigested DNAmate-
rial (presumably parasite DNA), representing 70% of the total
parasite DNA input that is available for NGS. Treated and non-
treated samples were both sequenced using Illumina sequencing.
The number of reads from untreated samples confirmed the orig-
inal proportions of parasite to humanDNA to be 1:10. Analysis of
reads from treated samples indicated up to a 9-fold enrichment of
the parasite DNA, from 10% to 92% of reads (Fig. 2A and B).
Mapping of reads obtained from treated samples to the P. falcip-
arum reference genome showed 100% coverage (Fig. 3B).
Enrichment assay on malaria clinical samples. After optimi-
zation of the enrichment assay using mock samples, we extended
these experiments to authentic malaria clinical samples contain-
ing human DNA contamination at levels ranging from 80 to
90%, as estimated by quantitative PCR. For the assay, each clinical
FIG 2 Analysis of sequence reads generated frommock samples (90% human
DNA contaminated) treated with or without MspJI enzyme. (A) Plots com-
paring the proportion of sequence readsmapping to the P. falciparum genome
in an untreated sample and treated sample with or without activator supple-
ment. (B) Plots comparing the proportion of sequence readsmapping to the P.
falciparum genome in untreated and treated samples; degraded human DNA
fragments were removed either following gel electrophoresis or with magnetic
beads. In both panels, error bars illustrate the deviation observed in 3 inde-
pendent replicates. Statistical differences were calculated using the unpaired
Student’s t test, with a P value of0.05 considered significant.
FIG 3 GC bias and whole-genome coverage analysis of mock samples treated
with or withoutMspJI. (A) GC content distribution profile for samples treated
and processed using different procedures. Libraries with GC contents above or
below 19.4% (theoretical) indicate base bias with respect to the P. falciparum 3D7
reference genome. (B) A plot of whole-genome coverage against average depth.
Variance in coverage depth above and below the normalized average depth (red
vertical line) across the genome is shown. Increaseddeviationof the sample curves
fromtheaveragedepth line indicates increased levelsofnonuniformity incoverage
depth distribution across the genome. The y-axis intercept indicates the percent-
age of the genome left uncovered. Pf-T, uncontaminated P. falciparum genomic
DNA treated with MspJI and processed with the gel electrophoresis procedure;
Pf-UT, uncontaminated P. falciparum genomic DNA processed with the gel elec-
trophoresis procedure without MspJI treatment (positive control); 90HsPf-UT,
human DNA contaminated (90%) with P. falciparum genomic DNA processed
with the gel electrophoresis procedure withoutMspJI treatment; 90HsPf-TGA, P.
falciparum genomic DNA contaminated with human DNA (90%) treated with
MspJI in thepresenceof activator sequence andprocessedwith the gel electropho-
resis procedure; 90HsPf-TGNA, P. falciparum genomic DNA contaminated with
human DNA (90%) treated with MspJI in the absence of activator sequence and
processed with the gel electrophoresis procedure; 90HsPf-TPS, P. falciparum
genomic DNA contaminated with human DNA (90%) treated withMspJI in the
absence of activator sequence andprocessedwith themagnetic bead size-selection
procedure.
TABLE 1 Average GC contenta
Sample
Avg % GC
content
Pf-UT 20.40 0.75
Pf-T 19.70 0.57
90HsPf-TGNA 21.58 0.45
90HsPf-TGA 22.06 0.45
90HsPf-TPS 19.99 1
90HsPf-UT 21.00 0.57
a Calculated values of average GC content corresponding to each library preparation.
For the P. falciparum 3D7 reference genome, a GC content above or below 19.4%
indicates bias. Figure 3A also shows a graphical view of the GC content distribution.
Sample name abbreviations are given in the legend to Fig. 3.
Oyola et al.
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sample was divided into two parts. One part was sequenced with-
out treatment, and the other was treated with the MspJI MD-RE
prior to sequencing. Degraded DNA was removed using gel sepa-
ration. We analyzed the sequence data generated and compared
treated versus untreated samples to determine the level of enrich-
ment as well as the quality of sequence data generated. About 80%
of the reads in the treated samples mapped to P. falciparum. We
down-sampled reads from treated samples—to match their cor-
responding untreated data sets—for enrichment analysis. We
show that between 4- and 7-fold enrichment of parasite DNAwas
achieved, depending on the extent of host contamination in the
original sample (Table 2; Fig. 4A). We also assessed cumulative
genome coverage and compared the depth and breadth of cover-
age for treated and untreated samples. As shown in Fig. 4B,95%
of the genome was covered 20 times or more in data from the
treated samples. In contrast, in the untreated samples, none (0%)
of the genome was covered at a depth greater than 20 times. In
addition to the 3 clinical samples that contained sufficient DNA to
perform both treated and untreated analyses, we also present data
for 14 other clinical samples that were subjected only to MD-RE
treatment followed by sequencing. As shown in Table S1 in the
supplemental material, we obtained enrichment values ranging
from3- to 13-fold; datawere of high quality, and coverage of theP.
falciparum reference genome was 100%.
Sequence analysis.Owing to the poor understanding of DNA
methylation status in many pathogenic organisms, we performed
extensive high-resolution comparative analysis of sequence data
generated from treated and untreated samples. To compare cor-
responding treated and untreated samples, total sequence read
data sets (before filtering host contamination)were normalized by
random down-sampling to generate matching numbers of reads
for analysis (Table 2). In this way, we assessed the quality of data
generated posttreatment. Base composition was assessed using
GC content analysis. Our results (Fig. 3A and 5A) indicate no
bias in base composition in treated samples that could be attrib-
uted to the effect of digestion. We also used evenness-of-coverage
metrics (13, 14) to analyze the distribution of coverage across the
entire genome for each sample.We did not detect any unintended
loss of sequence or uneven coverage as a result of treatment (Fig.
3B, samples Pf-T and Pf-UT). However, as expected, untreated
clinical samples with host contamination generated very few par-
asite-specific sequence reads, resulting in a very low depth of cov-
erage and with up to 10.3% of the parasite genome not being
covered at all (Fig. 3B, 4B, and 5B).
Coverage of typeable SNPs. To evaluate the quality and com-
plexity of sequence data generated following the host depletion
method, we analyzed the coverage of 86,158 high-quality single-
nucleotide polymorphisms (SNPs; typeable SNPs) that had previ-
ously been identified and used in determining P. falciparum pop-
ulation diversity (6). We analyzed the genome-wide coverage of
typeable SNPs in both untreated and treated samples from mock
(containing 90% human DNA by mass) and clinical samples. As
shown in Fig. 6A (mock samples) and Fig. 6B (clinical samples), all
treated samples (including 14 additional clinical samples shown in
Table S1 in the supplemental material) produced98% coverage
of typeable SNPs at a depth of5 times in all of the 14 P. falcipa-
rum chromosomes. On the other hand, none of the untreated
samples with host contamination achieved 80% coverage at 5
times in all chromosomes. Most importantly, coverage in the
treated samples was in concordance with the pure P. falciparum
DNA that was processed untreated (Pf-UT, positive control). This
indicated that host depletion treatment significantly enriched
pathogen material and improved coverage without bias toward
specific regions. The treatment maintained the complexity of the
genome, thereby producing quality parasite genome data, meet-
ing the required threshold for accurate SNP genotyping.
FIG 4 Analysis of sequence reads generated from clinical samples treated with
or withoutMspJI enzyme. (A) Plots showing the proportion of sequence reads
mapping to the P. falciparum genome in untreated samples and treated sam-
ples. (B) A plot showing the depth and breadth of the genome covered at
various read depths by treated and untreated samples. Sample names have a T
appended for MspJI treated and a UT appended for untreated. Host contam-
ination was as follows: 86% for PF312, 92% for PH0579, and 90% for PH0603.
All samples were processed using the gel separation procedure.
TABLE 2 Summary of sequence data information for host depletion
samplesa
Sample
No. of reads (106)
% reads
mapping
P. falciparum
Fold
enrichmentAvg
Down-
sampled
Pf-UTm 139.11 18.48 99.7 NA
Pf-Tm 37.96 18.48 99.6 0.5 NA
90HsPf-TGNAm 40.20 18.48 88.9 2 10
90HsPf-TGAm 50.94 18.48 88.9 1 10
90HsPf-TPSm 46.30 18.48 74.0 4 8
90HsPf-UTm 18.48 18.48 8.9 1 NA
PF312-UTc 10.32 10.32 16.9 NA
PF312-Tc 37.62 10.32 75.0 4.4
PH0579-UTc 16.39 16.39 11.7 NA
PH0579-Tc 42.37 16.39 83.9 7.2
PH0603-UTc 18.55 18.55 14.0 NA
PH0603-Tc 40.43 18.55 87.0 6.2
a Before filtering out human mapping reads (average number of reads), original data
sets were randomly down-sampled to generate a matching number of reads for
comparative analysis. Mock samples were analyzed in triplicate, and the data shown
represent average numbers of reads. m, mock samples; c, clinical samples; NA, not
applicable. Sample name abbreviations are as given in the legends to Fig. 3 and 4.
Depletion of Host Contamination in Clinical Sequencing
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DISCUSSION
Current solutions to host contamination include enrichment by
hybrid selection techniques inwhichDNAprobes complementary
to the pathogen nucleic acid are hybridized to the contaminated
sample. The captured pathogen DNA is pulled down and se-
quenced, while the nonhybridizing host contaminants are washed
away. Although these techniques improve sample quality (22–24),
they have numerous limitations and drawbacks. First, the oligo-
nucleotide baits (probes) are strain specific and expensive and
only partially remove the contaminating genome. Second, opti-
mal hybridization conditions for complete genome pulldown that
avoid nonspecific capture and bias are difficult to achieve. Third,
the current techniques require specialized skills and relatively
large quantities (at least 2 g) of starting DNA material to com-
plete the purification process (23). A traditional method for sep-
arating human andP. falciparumDNA involves the use ofHoechst
dye and ultracentrifugation in a CsCl gradient (25). This method
utilizes the inherent density differences between two DNA sam-
ples (e.g., human and P. falciparum) when their GC content is
significantly different. Although studies have reported successful
separation, the method is inefficient and suffers from poor sensi-
tivity. Furthermore, it is impractical if the quantity of starting
material is limited, as is the case with many clinical samples.
Herewe describe a novel approach to solve host contamination
problems using an enzymatic method that has the potential for
application to a wider range of pathogen samples. Unlike hybrid-
ization enrichment methods, the current technique is not limited
by the scope of oligonucleotide probes and therefore suitable for
WGS applications. Our tests show that MD-REs selectively de-
grade human DNA, thereby enriching malaria DNA in clinical
samples. We have used various analysis metrics and show that
MspJI treatment does not affect the quality and integrity of the
Plasmodium genome. Whereas other methods have been associ-
ated with base bias problems (22), our analysis has detected no
base bias associated with MspJI treatment. Evenness of genome
coverage by the treated samples was similar to that by pure un-
treated samples. A further evaluation of the quality of data gener-
ated by MspJI treatment involved testing the coverage of 86,158
high-quality typeable SNPs previously used in parasite diversity
studies (6). All treated samples were able to confidently call98%
of the typeable SNPs, including clinical sampleswith host contam-
ination of up to90%.
We further explored ways of making the treatment procedure
compatible with high-throughput automation. To this end, we
describe a gel-free option that makes the technique automation
friendly. The gel-free option usesmagnetic beads for size selection
and is particularly suitable for samples where the starting DNA
material is of limited quantity. However, the gel-free method suf-
fers from poorer yield (Fig. 2B), mainly due to the suboptimal size
separation by magnetic beads technology. The current enzyme
digestion time (16 h) can be shortened depending on the level of
FIG 5 GC bias and whole-genome coverage analysis of authentic clinical
samples treated or untreated with MspJI. (A) GC content distribution pro-
files. Libraries with GC content above or below 19.4% (theoretical) indicate
base bias with respect to the P. falciparum 3D7 reference genome. (B) A plot
showing uniformity of genome coverage against normalized average depth.
Variance in coverage depth above and below the normalized average depth
(red vertical line) across the genome is shown. Clinical isolates are PF312,
PH0579, and PH0603. Sample names have a T appended forMspJI treated and
a UT appended for untreated. Host contamination was as follows: 86% for
PF312, 92% for PH0579, and 90% for PH0603. All samples were processed
using the gel separation procedure.
FIG 6 Typeable SNP loci covered 5 times or more by treated and untreated
samples. A total of 86,158 typeable SNP positions across the entire genome
were analyzed for coverage at depths of 5 times or more. Themean percentage
of SNP positions covered per chromosome was computed for each sample.
The box plots show the mean and the variation of the percent coverage in the
14 chromosomes. (A) Mean percent coverage of the mock samples described
in Fig. 3; (B) mean percent coverage of the clinical samples described in Fig. 4.
Samples were treated without () or with () MspJI enzyme. Host contami-
nation was as follows: 86% for PF312, 92% for PH0579, and 90% for PH0603.
All samples were processed using the gel separation procedure.
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contamination. Future optimization of the enzyme purity and
buffer conditions may improve digestion efficiency.
The robustness and simplicity of the host depletion procedure
make it suitable for routine applications. The method is practical
even for poorly resourced clinical laboratories near the field,
which process clinical samples before sending the DNA to larger
sequencing centers. The technology is relatively rapid and cost-
effective, with an estimated treatment cost of only $4 per sample.
Conclusion. Host contamination in pathogen clinical se-
quencing is currently a major problem. The current development
has the potential to alleviate human DNA contamination prob-
lems in clinical sequencing. Implementation will not only reduce
the time and cost of pathogen sequencing for health care but also
increase the sampling density of culture-free field isolates for con-
trol, research, and public health sequencing applications.
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